Skip to main content
SNY
NASDAQ Life Sciences

Sanofi Appoints Belén Garijo as CEO, Declares €4.12 Dividend, and Welcomes New Director

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$43.48
Mkt Cap
$109.521B
52W Low
$43.15
52W High
$55.73
52W Position info
0.8% above low
Off High info
22% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SNY is trading near its 52-week low of $43.15 (0.8% above the low).

Summary

Sanofi's Annual General Meeting approved the appointment of Belén Garijo as the new CEO, effective May 1, 2026, alongside the declaration of a €4.12 annual dividend and the addition of Christel Heydemann to the board.


Key Events · Executive and Board Changes · SNY

  • New Chief Executive Officer Appointed

    Belén Garijo was formally appointed as Director and Chief Executive Officer, effective May 1, 2026, following shareholder approval at the Annual General Meeting. Her mandate includes strengthening execution discipline and refining capital allocation.

  • Annual Dividend Declared

    Shareholders approved an ordinary annual dividend of €4.12 per share, with payment scheduled for May 7, 2026.

  • New Independent Director Joins Board

    Christel Heydemann, CEO of Orange, was appointed as an independent board member, bringing experience in Digital and AI technologies to the board.


Analysis · SNY · Life Sciences

This filing signals a significant leadership transition and a commitment to shareholder returns for Sanofi. The appointment of Belén Garijo as CEO, effective May 1, 2026, brings a leader with a strong track record in R&D, strategy, and business transformation, with a mandate to strengthen execution and capital allocation. This decisive leadership change, coupled with the declaration of a substantial €4.12 annual dividend, may be aimed at reassuring investors and driving performance, especially as the company's stock is currently trading near its 52-week low. The addition of Christel Heydemann, CEO of Orange, as an independent board member further strengthens governance with expertise in digital and AI technologies.

At the time of this filing, SNY was trading at $43.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109.5B. The 52-week trading range was $43.15 to $55.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNY - Latest Insights

SNY
Aug 06, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $43.26
Real-time Price: $43.63 info
Change: +$0.370 (+0.86%) info
Market Cap: $102.687B info
SNY
Jul 30, 2026, 7:34 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $43.66
Real-time Price: $43.63 info
Change: -$0.030 (-0.07%) info
Market Cap: $102.687B info
SNY
Jul 30, 2026, 6:28 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $43.47
Real-time Price: $43.63 info
Change: +$0.160 (+0.37%) info
Market Cap: $102.687B info
SNY
Jul 27, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $43.90
Real-time Price: $43.63 info
Change: -$0.270 (-0.62%) info
Market Cap: $102.687B info
SNY
Jul 10, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $43.69
Real-time Price: $43.63 info
Change: -$0.060 (-0.14%) info
Market Cap: $102.687B info